Table 1.
Baseline demographics
| Baseline characteristics | Included subjects (n=10) |
|---|---|
| Age in years | 67 (7) |
| Gender | 60% women, 40% men |
| Hypertension | 40% |
| Coronary artery disease | 0% |
| Hyperlipidemia | 10% |
| Baseline cognitive assessment | |
| Mini-Mental State Examination | 24 (3) |
| Cognitive Assessment Screening Test | 29.6 (5) |
| Clinical Dementia Rating scale | 1 (0.47) |
| ADAS-cog 13 | 31 (7) |
| Serology | |
| C-reactive protein (mg/L) | 1.4 (1.8) |
| Low-density lipoprotein (mg/dL) | 137.2 (26.7) |
| High-density lipoprotein (mg/dL) | 58.2 (19.2) |
| Total cholesterol (mg/dL) | 223.9 (32.3) |
| Triglycerides (mg/dL) | 133.1 (66.9) |
| Creatine phosphokinase (U/L) | 69 (36.86) |
| Thyroid-stimulating hormone (mU/L) | 2.92 (2.33) |
| Vitamin B12 (pg/mL) | 506 (359) |
| Erythrocyte sedimentation rate (mm/h) | 8.8 (5.9) |
| International normalized ratio | 1.0 (0.1) |
| Medication use | |
| Donepezil or rivastigmine | 80% |
| Memantine | 40% |
| Psychotropic use | 70% |
| Anticholinergic drug usea | 30% |
| Apolipoprotein E (APOE) genotyping (n=9) | |
| APOE-3,3 | 1 (11%) |
| APOE-3,4 | 5 (56%) |
| APOE-4,4 | 3 (33%) |
| Cerebral spinal fluid phosphorylated tau (n=7) | |
| High (>68 pg/mL) | 3(43%) |
| Intermediate (55–67 pg/mL) | 1 (14%) |
| Normal (<54 pg/mL) | 3 (43%) |
ADAS-cog 13 indicates Alzheimer’s Disease Assessment Scale-cognitive 13. Data are shown as mean±sd or %. aMost commonly diphenhydramine